Abstract
Introduction: Lupus nephritis (LN) is one of the most serious complications in the development of systemic lupus erythematosus, that can adversely affect the course and prognosis of this autoimmune disease. Therefore, monitoring the effect of applied therapy, achieving remission, or monitoring LN activity is still a great challenge for nephrologists. This study aimed to compare the urinary neutrophile gelatinase associated lipocalin (u/NGAL) with traditionally accepted parameters for LN activity to indicate the importance of its determination in these patients.
Methods: The study group consisted of 40 patients, who were prospectively followed for a period of 4 months within three control visits to 2 months. The first group (20/40) had active LN (Group A), and the second group had LN in remission (Group B). The parameters were compared: proteins/s, albumins/s, C3, C4, anti-ds-DNA Ab, proteinuria 24h, ur.protein / creatinine ratio - Up / cre, u/NGAL (immunochemical method CMIA),GFR.
Results: Comparing standard parameters of disease activity and NGAL/u between groups, a statistically significant difference was obtained (p <0.001). Within Group A, comparing the parameters (X ± SD) by visits (0 : 2) for anti-ds-DNA Ab a significance of p <0.05 was obtained, for albumin / s and C3 a significance of p <0.01 was obtained, and proteinuria / 24h, Upr / Cre, u/NGAL had a significance of p <0.001. The negative correlation of u/NGAL was statistically significant at initial visit with albumin/s (p <0.01) as well as the positive correlation with proteinuria 24h and Up / cre (p <0.001). In visit 2 significant negative correlation of u/NGAL with albumin /s and C3 p <0.05, and positive correlation with anti-ds-DNA Ab, proteinuria 24h and Up/cre p <0.001.
Conclusion: In our study, the biomarker u/NGAL, showed a statistically significant correlation with traditional parameters of lupus nephritis activity, and its determination could be significant in monitoring LN activity and monitoring responses to applied treatment.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.